2. Search Result
Search Result
Results for "

Obicetrapib hemicalcium

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-18778C
    Obicetrapib hemicalcium

    TA-8995 hemicalcium; DEZ-001 hemicalcium; AMG-899 hemicalcium

    		 CETP PCSK9 LDLR Inflammation/Immunology
    Obicetrapib calcium is an orally active cholesteryl ester transfer protein (CETP) inhibitor. Obicetrapib calcium shifts the plasma lipoprotein profile toward more HDL-C particles, reduces circulating PCSK9 levels, increases hepatic LDLR expression and LDLR mRNA levels, and promotes hepatic clearance of VLDL remnants. Obicetrapib calcium increases the number of large HDL particles, reduces the number and area of atherosclerotic lesions and alleviates lesion severity, increases the proportion of unaffected arterial segments, improves lesion stability, and promotes regression of aortic root lesions. It also exerts a synergistic effect with Ezetimibe (HY-17376) to reduce non-HDL-C levels and improve atherosclerosis. Obicetrapib calcium can be used in studies related to atherosclerosis and dyslipidemia .
    Obicetrapib hemicalcium

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: